Summary Sheet Figures and Maps Ministry of Health, Lesotho, Centers for Disease Control and Prevention (CDC), and ICAP at Columbia University. Lesotho Population-based HIV Impact Assessment (LePHIA) 2015-16: Summary Sheet. Maseru, Lesotho, Atlanta, Georgia and New York, New York, USA: Ministry of Health, CDC and ICAP. November 2017. The mark “CDC” is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise. This project is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of cooperative agreement #U2GGH001226. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies Updated December 2018

HIV Prevalence by Age and Sex, LePHIA 2016-2017 HIV prevalence peaks at 49.9% among females ages 35 to 39 as compared to 46.9% among males ages 40 to 44 years. The disparity in HIV prevalence by sex is most pronounced among young adults: HIV prevalence among 20- to 24-year-olds is four times as high among females (16.7%) than males (4.0%). Error bars represent 95% confidence intervals.

HIV Prevalence Among Adults, by District, LePHIA 2016-2017 Among adults ages 15 to 59 years, prevalence of HIV varies geographically across Lesotho, ranging from a low of 17.8% in Botha-Bothe to a high of 29.3% in Mohale’s Hoek. HIV Prevalence Among Adults, by District, LePHIA 2016-2017

Viral Load Suppression Among HIV-Positive People, by Age and Sex, LePHIA 2016-2017 Prevalence of VLS among HIV-positive people in Lesotho is highest among older people ages 45 to 59 years: 80.3% among HIV-positive females and 81.4% among HIV-positive males. In contrast, prevalence of VLS is distinctly lower among younger adults: 50.9% among HIV-positive females ages 15 to 24 years and 46.1% among HIV-positive males ages 25 to 34 years. Error Bars represent 95% confidence intervals.

Viral Load Suppression Among HIV-Positive Adults, by District, LePHIA 2016-2017

Achievement of the 90-90-90 Goals Among HIV-Positive Adults, by Sex, LePHIA 2016-2017 90–90–90: An ambitious treatment target to help end the AIDS epidemic By 2020, 90% of all PLHIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy (ART); and 90% of all people receiving ART will have viral suppression. Diagnosed In Lesotho, 81.0% of PLHIV ages 15 to 59 years report knowing their HIV status: 84.0% of HIV-positive females and 76.6% of HIV-positive males know their HIV status. Knowledge of status was defined as self-reporting HIV positive and/or having a detectable antiretroviral (ARV) in the blood. On Treatment Among PLHIV ages 15 to 59 years who know their HIV status, 91.8% report current use of ART: 92.0% of HIV-positive females and 91.6% of HIV-positive males who know their HIV status report current use of ART. Current use of ART was defined as reporting current use of ART and/or having a detectable ARV in the blood. Virally Suppressed Among PLHIV ages 15 to 59 years who report current use of ART, 87.7% are virally suppressed: 87.7% of HIV-positive females and 87.7% of HIV-positive males who report current use of ART are virally suppressed. *Inset numbers are conditional proportions. Error bars represent 95% confidence intervals. Diagnosed: awareness was defined as self-reporting HIV positive and/ or having a detectable antiretroviral (ARV) in the blood. On Treatment: being on ART was defined as self-reporting current use of ART and/or having a detectable ARV in the blood.

Find the LePHIA Summary Sheet and additional PHIA Project results at: phia.icap.columbia.edu The mark “CDC” is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise. This project is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of cooperative agreement #U2GGH001226. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies